Backup Blog — BLOODPAC

July 2, 2026

BLOODPAC Quarterly Newsletter: 2026 Q2

July 2, 2026

Read more →

July 2, 2026

May 13, 2026

Believe in Progress: An #AACR Foundation Podcast

May 13, 2026

Lauren C. Leiman, Executive Director of BLOODPAC, and Mary Royal, a breast cancer survivor and ctDNA testing advocate, sat down with Believe in Progress: An #AACR Foundation Podcast host Mitchell Stoller to discuss the evolving role of liquid biopsy in cancer care.

Read more →

May 13, 2026

April 14, 2026

BLOODPAC Quarterly Newsletter: 2026 Q1

April 14, 2026

Read more →

April 14, 2026

January 28, 2026

BLOODPAC Quarterly Newsletter: 2025 Q4

January 28, 2026

Read more →

January 28, 2026

November 17, 2025

Performance with Metrics in Early Detection

November 17, 2025

In this blog we recap our Early Detection & Screening (ED&S) Working Group’s summer seminar “Performance with Purpose: Metrics that Inform Clinical and Public Health Decisions,” which took place virtually on August 20 at 11:00 AM ET.

Read more →

November 17, 2025

October 5, 2025

BLOODPAC Quarterly Newsletter: 2025 Q3

October 5, 2025

Read more →

October 5, 2025

July 2, 2025

BLOODPAC Quarterly Newsletter: 2025 Q2

July 2, 2025

Read more →

July 2, 2025

April 16, 2025

BLOODPAC Quarterly Newsletter: 2025 Q1

April 16, 2025

Read more →

April 16, 2025

January 6, 2025

BLOODPAC Quarterly Newsletter: 2024 Q4

January 6, 2025

Read more →

January 6, 2025

August 26, 2024

New Op-Ed in STAT News: Address liquid biopsy disparities today to ensure equity in outcomes tomorrow

August 26, 2024

Read more →

August 26, 2024

August 23, 2024

BLOODPAC Quarterly Newsletter: 2024 Q1-Q2

August 23, 2024

Read more →

August 23, 2024

June 17, 2024

Rethinking risk and risk assessment for liquid biopsy-based single- & multi-cancer screening

June 17, 2024

At the 2024 annual meeting of the American Association for Cancer Research (AACR), BLOODPAC’s Early Detection and Screening Working Group (ED&S WG) hosted a session focusing on cancer risk and risk assessment for liquid biopsy-based single- and multi-cancer screening.

Read more →

June 17, 2024

May 28, 2024

BLOODPAC and JCO Precision Oncology Conversations

May 28, 2024

Lauren Leiman, Executive Director at BLOODPAC and Dr. Emma Alme, Public Policy Director at Guardant Health sat down with JCO Podcast host, Dr. Rafeh Naqash to discuss accessibility to liquid biopsy for cancer, potential barriers and proposed solutions.

Read more →

May 28, 2024

September 26, 2023

BLOODPAC Quarterly Newsletter: 2023 Q3

September 26, 2023

Read more →

September 26, 2023

August 2, 2023

Understanding Circulating Tumor Cell-Based Liquid Biopsy

August 2, 2023

In this article, we explore the identification, characterization, analysis, and clinical applications of circulating tumor cells in blood-based liquid biopsy for cancer management.

Read more →

August 2, 2023

July 7, 2023

Understanding Liquid Biopsy for Early Cancer Detection and Screening

July 7, 2023

Advances in cancer detection have historically lagged behind the development of new cancer treatments. Liquid biopsy is poised to change this. The development of blood-based cancer detection assays in the past several years has led to numerous high-profile studies and hundreds of thousands of individuals enrolled in clinical trials.

Read more →

July 7, 2023

June 15, 2023

BLOODPAC Quarterly Newsletter: 2023 Q2

June 15, 2023

Read more →

June 15, 2023

May 1, 2023

Understanding BLOODPAC’s Analytical Validation Protocols for Late-Stage Solid Tumor ctDNA Assays

May 1, 2023

Read more →

May 1, 2023

April 20, 2023

Understanding Liquid Biopsy for Brain Cancer

April 20, 2023

Any cancer diagnosis is devastating, but the discovery of a brain tumor comes with a unique set of challenges for both patient and doctor. In this article, we discuss the potential role of liquid biopsy for management of brain cancer, current research in this space, and remaining questions in the field.

Read more →

April 20, 2023